Columbia University Herbert Irving Comprehensive Cancer Center, New York, New York.
Department of Urology, Columbia University Medical Center, New York, New York.
Clin Cancer Res. 2021 Aug 1;27(15):4139-4141. doi: 10.1158/1078-0432.CCR-21-1011. Epub 2021 May 27.
The majority of patients with urothelial cancer do not respond to immune checkpoint blockade directed at the PD-(L)1 axis. Recently, robust profiling data were used to derive predictive biomarker signatures for both protumorigenic immunity and adaptive antitumor immunity; combining these has greater predictive power than either alone. Clinically, these results suggest that myeloid cells may be primary drivers of nonresponsiveness in urothelial cancer..
大多数膀胱癌患者对针对 PD-(L)1 轴的免疫检查点阻断治疗无反应。最近，大量的特征分析数据被用于为促肿瘤免疫和适应性抗肿瘤免疫衍生预测生物标志物特征；将这两者结合起来比单独使用其中任何一种具有更大的预测能力。临床上，这些结果表明髓样细胞可能是膀胱癌无反应的主要驱动因素。
